Urinary and Blood Concentrations of β₂-Agonists in Trained Subjects: Comparison between Routes of Use

Abstract

We aimed to assess the plasma and urine concentrations of β₂-agonists and evaluate the difference between three routes of administration in trained adults in order to distinguish doping from prevention of exercise-induced asthma. Ten young healthy Caucasian male subjects received during a four treatment period study: 1) inhaled salbutamol (S_I) 2 × 100 µg t.i.d. for 3 days, 2) inhaled formoterol (F_I) 2 × 12 µg b.i.d. for 3 days, 3) a single subcutaneous injection of salbutamol (S_S) 0.5 mg, and 4) salbutamol 2 × 2 mg t.i.d. orally for 3 days (S_O). Blood samples were taken during the first and the third day of experimentation at baseline, 30 min, 1 h, 2 h, 4 h and 6 h after administration; additional blood samples were drawn at 15 min for S_I, S_S and F_I and at 12 h for F_I. Urinary samples were collected at baseline, 2 h, 4 h, 6 h and 12 h after administration. Urinary concentrations were 20 to almost 50 times higher after S_O than after S_I. Mean urinary concentration after S_O increased to above 800 ng · mL^-1 within the two hours and above 1000 ng · mL^-1 at 6 to 12 hours post-drug administration. Urinary concentrations after S_S were maximal during the first 2 hours (mean: 340 ± 172 ng · mL^-1). Plasma concentrations were very low, whatever the routes of administration. Results showed that we could eliminate the use of S_I (authorized) and S_S administration when individual urinary concentrations are higher than 230 ng · mL^-1 and 615 ng · mL^-1, respectively. Therefore, at rest, the cut-off value used to discriminate therapeutic from doping salbutamol intake could be fixed at 250 ng · mL^-1 instead of the 1000 ng · mL^-1 still authorized by international committees.

β₂-agonists - doping - asthma - plasma and urinary concentrations

References

• 1 Berges R, Segura J, Ventura R, Fitch K D, Morton A R, Farre M, Mas M, de la Torre X. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.  Clin Chem. 2000;  46 1365-1375
• 2 Berges R, Segura J, de la Torre X, Ventura R. Analytical methodology for enantiomers of salbutamol in human urine for application in doping control.  J Chromatogr B Biomed Sci Appl. 1999;  723 173-184
• 3 Boulton D W, Fawcett J P. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography.  J Chromatogr B Biomed Appl. 1995;  672 103-109
• 4 Carlsen K H, Hem E, Stensrud T, Held T, Herland K, Mowinckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.  Respir Med. 2001;  95 571-576
• 5 Collomp K, Candau R, Collomp R, Carra J, Lasne F, Prefaut C, De Ceaurriz J. Effects of acute ingestion of salbutamol during submaximal exercise.  Int J Sports Med. 2000;  21 480-484
• 6 Collomp K, Candau R, Lasne F, Labsy Z, Prefaut C, De Ceaurriz J. Effects of short-term oral salbutamol administration on exercise endurance and metabolism.  J Appl Physiol. 2000;  89 430-436
• 7 Fleck S J, Lucia A, Stroms W W, Wallach J M, Vint P F, Zimmerman S O. Effects of acute inhalation of albuterol on submaximal and maximal V·O₂ and blood lactate.  Int J Sports Med. 1993;  14 239-243
• 8 Freeman W, Packe G E, Cayton R M. Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.  Thorax. 1989;  44 942-947
• 9 Goubault C, Perault M C, Leleu E, Bouquet S, Legros P, Vandel B, Denjean A. Effects of inhaled salbutamol in exercising non-asthmatic athletes.  Thorax. 2001;  56 675-679
• 10 Hankinson J L, Bang K M. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population.  Am Rev Respir Dis. 1991;  143 516-521
• 11 Meeuwisse W H, McKenzie D, Hopkins S R, Road J D. The effect of salbutamol on performance in elite non-asthmatic athletes.  Med Sci Sports Exerc. 1992;  24 1161-1166
• 12 Morton A R, Papalia S M, Fitch K D. Is salbutmol ergogenic? The effect of salbutamol on physical performance in high-performance non-asthmatic athletes.  Clin J Sports Med. 1992;  2 93-97
• 13 Roig M, Berges R, Ventura R, Fitch K D, Morton A R, Segura J. Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations.  J Chromatogr B Analyt Technol Biomed Life Sci. 2002;  768 315-324
• 14 Schmidt A, Diamant B, Bundgaard A, Madsen P L. Ergogenic effect of inhaled β2-agonists in asthmatics.  Int J Sports Med. 1988;  9 338-340
• 15 Shapiro G S, Yegen U, Xiang J, Kottakis J, Della Cioppa G. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol.  Clin Ther. 2002;  24 2077-2087
• 16 Signorile J F, Kaplan T A, Applegate B, Perry A C. Effects of acute inhalation of the bronchodilatator, albuterol, on power output.  Med Sci Sports Exerc. 1992;  24 638-642
• 17 van Noord J A, Smeets J J, Raaijmakers J A, Bommer A M, Maesen F P. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.  Eur Respir J. 1996;  9 1684-1688
• 18 Ventura R, Segura J, Fitch K D, Morton A R, Berges R, Jimenez C, Berruezo S. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.  Ther Drug Monit. 2000;  22 277-282
• 19 Voy R O. The U. S. Olympic Committee experience with exercise-induced bronchospasm.  Med Sci Exerc. 1986;  18 328-330
• 20 Weiler J M, Layton T, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games.  J Allergy Clin Immunol. 1998;  102 722-726
• 21 World Anti-Doping Agency .The 2004 Prohibited List. Montreal, Quebec, Canada; World Anti-Doping Code 2004: 5